Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01508390 · ClinicalTrials.gov registry record · NA

Hypofractionated Stereotactic Body Radiation Therapy as a Boost to the Prostate

A NA study of Prostate Cancer, sponsored by Boston Medical Center.

Active
Registry status
NA
Development phase
35
Enrollment target
1
Study location

NCT01508390 is a NA study of Prostate Cancer that is active but no longer recruiting, run by Boston Medical Center. The registered enrollment target is 35 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01508390, a NA study of Prostate Cancer, is active but no longer recruiting, sponsored by Boston Medical Center.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
35 participants
Enrollment target
1
Study location

Study Summary

In this study, participants will have standard Androgen Deprivation Therapy and undergo standard external beam radiation therapy to the prostate and at-risk lymph nodes by Intensity Modulated Radiation Therapy. The subsequent \*boost\* radiation therapy to the prostate alone will be given using the CyberKnife, rather than using the standard Intensity Modulated Radiation Therapy. This study will also see how CyberKnife affects the quality of the participant's life.

Conditions Studied

Interventions

  • RADIATION CyberKnife Boost

Study Locations (1)

Massachusetts

  • Boston Medical Center - Boston

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 2011-06
Est. Completion 2027-12
Phase NA

Sponsor

Boston Medical Center

253 total trials

What the Registry Record Tells You About NCT01508390

The ClinicalTrials.gov registry entry for NCT01508390 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Boston Medical Center, which has 253 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which CyberKnife Boost is the first listed.

NCT01508390 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT01508390 about?

NCT01508390 is a clinical study titled "Hypofractionated Stereotactic Body Radiation Therapy as a Boost to the Prostate". In this study, participants will have standard Androgen Deprivation Therapy and undergo standard external beam radiation therapy to the prostate and at-risk lymph nodes by Intensity Modulated Radiation Therapy. The subsequent \*boost\* radiation therapy to the prostate alone will be given using the ...

What is the current status of trial NCT01508390?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 35 participants. The study started on 2011-06. Estimated completion is 2027-12.

What conditions does trial NCT01508390 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT01508390?

The interventions under investigation include: CyberKnife Boost (RADIATION).

Who is sponsoring clinical trial NCT01508390?

This trial is sponsored by Boston Medical Center, which has 253 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01508390 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.